FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324137050> ?p ?o ?g. }

• W4324137050 endingPage "166" @default.
• W4324137050 startingPage "166" @default.
• W4324137050 abstract "166 Background: About 2/3 of all prostate cancer (PCa) deaths occur in patients aged ≥75, who are frequently diagnosed with advanced PCa. ARSi abiraterone acetate (AA) and enzalutamide (E) are the most common 1 st line Rx for patients with mCRPC. Yet, the optimal treatment sequence for the elderly ≥75 after ARSi failure is still unclear. Methods: Using available medical records, patients aged ≥75 who started ARSi as 1 st line Rx for mCRPC within January 2015 - April 2019 and, upon progression, 2 nd line alternative ARSi or D were identified from the IRB approved hospital registries of 10 centers in Europe, North and South America. Patients were categorized by type of 2 nd line Rx for mCRPC into cohorts AA/E and D. Primary endpoints were overall survival (OS) from 1 st line AA/E start, OS and radiographic progression-free survival (rPFS) from 2 nd line Rx start, and safety. The Kaplan Meier method was used to calculate endpoint distributions and medians (95% CI). Results: Of the 122 patients identified, 57 (46.7%) had AA/E and 65 (53.3%) D, as 2 nd line Rx for mCRPC. Median follow-up was 26.3 months (95% CI, 23.1-27.9 months). Cohort AA/E tended to be older (81 vs 78 years; p=0.001) and with high-volume disease (45.5% vs 25.0%; p=0.022) compared to cohort D. No significant difference in OS from 1 st line ARSi onset and OS or rPFS from 2 nd line Rx start was found between the 2 cohorts. Cohort AA/E had longer rPFS than cohort D, albeit not significant (18.5 vs 12.0 months; p=0.13). Rates of adverse events (AEs) of any grade (42.1 vs 53.8; p=0.21) and AEs of grade ≥3 (19.3% vs 18.5%; p=1.0) did not show significant differences between the 2 cohorts. Conclusions: Within the limitations of small cohorts and retrospective design, treatment sequences with 2 nd line AA/E or D after failure of 1 st line alternative ARSi for mCRPC showed similar efficacy and safety in the elderly ≥75 years old." @default.
• W4324137050 created "2023-03-15" @default.
• W4324137050 creator A5009277251 @default.
• W4324137050 creator A5012723210 @default.
• W4324137050 creator A5016156453 @default.
• W4324137050 creator A5017866134 @default.
• W4324137050 creator A5018153995 @default.
• W4324137050 creator A5036125918 @default.
• W4324137050 creator A5036946878 @default.
• W4324137050 creator A5037646183 @default.
• W4324137050 creator A5039705474 @default.
• W4324137050 creator A5042146146 @default.
• W4324137050 creator A5047133719 @default.
• W4324137050 creator A5053905496 @default.
• W4324137050 creator A5057926104 @default.
• W4324137050 creator A5071060598 @default.
• W4324137050 creator A5074461929 @default.
• W4324137050 creator A5078631166 @default.
• W4324137050 creator A5081355165 @default.
• W4324137050 creator A5086693874 @default.
• W4324137050 creator A5089327773 @default.
• W4324137050 creator A5091765229 @default.
• W4324137050 date "2023-02-20" @default.
• W4324137050 modified "2023-09-28" @default.
• W4324137050 title "Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study." @default.
• W4324137050 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.166" @default.
• W4324137050 hasPublicationYear "2023" @default.
• W4324137050 type Work @default.
• W4324137050 citedByCount "0" @default.
• W4324137050 crossrefType "journal-article" @default.
• W4324137050 hasAuthorship W4324137050A5009277251 @default.
• W4324137050 hasAuthorship W4324137050A5012723210 @default.
• W4324137050 hasAuthorship W4324137050A5016156453 @default.
• W4324137050 hasAuthorship W4324137050A5017866134 @default.
• W4324137050 hasAuthorship W4324137050A5018153995 @default.
• W4324137050 hasAuthorship W4324137050A5036125918 @default.
• W4324137050 hasAuthorship W4324137050A5036946878 @default.
• W4324137050 hasAuthorship W4324137050A5037646183 @default.
• W4324137050 hasAuthorship W4324137050A5039705474 @default.
• W4324137050 hasAuthorship W4324137050A5042146146 @default.
• W4324137050 hasAuthorship W4324137050A5047133719 @default.
• W4324137050 hasAuthorship W4324137050A5053905496 @default.
• W4324137050 hasAuthorship W4324137050A5057926104 @default.
• W4324137050 hasAuthorship W4324137050A5071060598 @default.
• W4324137050 hasAuthorship W4324137050A5074461929 @default.
• W4324137050 hasAuthorship W4324137050A5078631166 @default.
• W4324137050 hasAuthorship W4324137050A5081355165 @default.
• W4324137050 hasAuthorship W4324137050A5086693874 @default.
• W4324137050 hasAuthorship W4324137050A5089327773 @default.
• W4324137050 hasAuthorship W4324137050A5091765229 @default.
• W4324137050 hasConcept C121608353 @default.
• W4324137050 hasConcept C126322002 @default.
• W4324137050 hasConcept C143998085 @default.
• W4324137050 hasConcept C203092338 @default.
• W4324137050 hasConcept C2775832370 @default.
• W4324137050 hasConcept C2776551883 @default.
• W4324137050 hasConcept C2777899217 @default.
• W4324137050 hasConcept C2780192828 @default.
• W4324137050 hasConcept C2781190966 @default.
• W4324137050 hasConcept C535046627 @default.
• W4324137050 hasConcept C61367390 @default.
• W4324137050 hasConcept C71924100 @default.
• W4324137050 hasConcept C72563966 @default.
• W4324137050 hasConceptScore W4324137050C121608353 @default.
• W4324137050 hasConceptScore W4324137050C126322002 @default.
• W4324137050 hasConceptScore W4324137050C143998085 @default.
• W4324137050 hasConceptScore W4324137050C203092338 @default.
• W4324137050 hasConceptScore W4324137050C2775832370 @default.
• W4324137050 hasConceptScore W4324137050C2776551883 @default.
• W4324137050 hasConceptScore W4324137050C2777899217 @default.
• W4324137050 hasConceptScore W4324137050C2780192828 @default.
• W4324137050 hasConceptScore W4324137050C2781190966 @default.
• W4324137050 hasConceptScore W4324137050C535046627 @default.
• W4324137050 hasConceptScore W4324137050C61367390 @default.
• W4324137050 hasConceptScore W4324137050C71924100 @default.
• W4324137050 hasConceptScore W4324137050C72563966 @default.
• W4324137050 hasIssue "6_suppl" @default.
• W4324137050 hasLocation W43241370501 @default.
• W4324137050 hasOpenAccess W4324137050 @default.
• W4324137050 hasPrimaryLocation W43241370501 @default.
• W4324137050 hasRelatedWork W2263206436 @default.
• W4324137050 hasRelatedWork W2770702948 @default.
• W4324137050 hasRelatedWork W2776594178 @default.
• W4324137050 hasRelatedWork W3023947295 @default.
• W4324137050 hasRelatedWork W3156855168 @default.
• W4324137050 hasRelatedWork W4205706045 @default.
• W4324137050 hasRelatedWork W4226040508 @default.
• W4324137050 hasRelatedWork W4229076799 @default.
• W4324137050 hasRelatedWork W4293582883 @default.
• W4324137050 hasRelatedWork W4312262256 @default.
• W4324137050 hasVolume "41" @default.
• W4324137050 isParatext "false" @default.
• W4324137050 isRetracted "false" @default.
• W4324137050 workType "article" @default.